Traditional Chinese medicine baoxin decoction improves cardiac fibrosis of rats with dilated cardiomyopathy

Sun,Rongrong; Wang,Jiangbo; Zheng,Yi; Li,Xianchi; Xie,Tiantian; Li,Rui; Liu,Min; Cao,Yong; Lu,Lei; Zhang,Qing; Zhang,Peiying

doi:10.3892/etm.2017.4223

Traditional Chinese medicine baoxin decoction improves cardiac fibrosis of rats with dilated cardiomyopathy

Authors:
- Rongrong Sun
- Jiangbo Wang
- Yi Zheng
- Xianchi Li
- Tiantian Xie
- Rui Li
- Min Liu
- Yong Cao
- Lei Lu
- Qing Zhang
- Peiying Zhang
View Affiliations

Affiliations: Clinical Medicine, Nanjing University of Traditional Chinese Medicine, The Affiliated Xuzhou Central Hospital of Nanjing University of Traditional Chinese Medicine, Nanjing, Jiangsu 210023, P.R. China, Department of Neurology, Xuzhou Central Hospital, Xuzhou, Jiangsu 221009, P.R. China, Department of Cardiology, Xuzhou Central Hospital, Xuzhou, Jiangsu 221009, P.R. China, Department of Cardiology, Xuzhou Hospital of Traditional Medicine, Xuzhou, Jiangsu 221009, P.R. China, Department of Cardiology, The Affiliated Xuzhou Central Hospital of Nanjing University of Traditional Chinese Medicine, The Affiliated Xuzhou Hospital of Medical School of Southeast University, Xuzhou, Jiangsu 221009, P.R. China
Published online on: March 10, 2017 https://doi.org/10.3892/etm.2017.4223
Pages: 1900-1906
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

We investigated the effect of baoxin decoction (BXD) on myocardial fibrosis and clarified the possible mechanism of action. Dilated myocardiopathy was induced by doxorubicin injected intraperitoneally for 6 weeks. Rats that demonstrated dilated myocardiopathy were randomly divided into five groups plus a control group. Three groups were treated with BXD (7.5/kg, 15 g/kg and 30 g/kg) daily for 4 weeks. One group was treated with 8.75 g/kg of captopril (positive control), and with physiologic saline (negative control). Cardiac function was evaluated using echocardiography. Hematoxylin and eosin, and Masson's trichrome staining were performed, PICP and PIIINP were assessed by ELISA, the expression of galectin-3 and collagen types Ⅰ and Ⅲ was evaluated with reverse transcription‑quantitative PCR, and interrelated proteins were detected by western blot analysis. BXD downregulated galectin-3, collagen Ⅰ and Ⅲ and was correlated with a high expression of fibrosis markers. It also significantly decreased myocardial collagen volume fraction (CVF), together with markedly preventing the upregulation of collagen Ⅰ and Ⅲ. In addition, BXD downregulated the expression of TGF-β1 and Smad3 in the myocardial fibrosis rats. Therefore, BXD treatment significantly improved cardiac function and alleviated myocardial fibrosis in a rat model of doxorubicin-induced dilated cardiomyopathy (DCM), which is the mechanism that may be associated with inhibiting the TGF-β1 signaling pathway.

View Figures

View References

1	Gopal DM and Sam F: New and emerging biomarkers in left ventricular systolic dysfunction - Insight into dilated cardiomyopathy. J Cardiovasc Transl Res. 6:516–527. 2013. View Article : Google Scholar : PubMed/NCBI
2	Towbin JA, Lowe AM, Colan SD, Sleeper LA, Orav EJ, Clunie S, Messere J, Cox GF, Lurie PR, Hsu D, et al: Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA. 296:1867–1876. 2006. View Article : Google Scholar : PubMed/NCBI
3	Luk A, Ahn E, Soor GS and Butany J: Dilated cardiomyopathy: A review. J Clin Pathol. 62:219–225. 2009. View Article : Google Scholar : PubMed/NCBI
4	Carasso S and Amir O: Reverse remodeling in dilated cardiomyopathy: Dream come true? Isr Med Assoc J. 16:444–445. 2014.PubMed/NCBI
5	Nicolini G, Pitto L, Kusmic C, Balzan S, Sabatino L, Iervasi G and Forini F: New insights into mechanisms of cardioprotection mediated by thyroid hormones. J Thyroid Res. 2013:2643872013. View Article : Google Scholar : PubMed/NCBI
6	Jalil JE, Doering CW, Janicki JS, Pick R, Shroff SG and Weber KT: Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res. 64:1041–1050. 1989. View Article : Google Scholar : PubMed/NCBI
7	Kong P, Christia P and Frangogiannis NG: The pathogenesis of cardiac fibrosis. Cell Mol Life Sci. 71:549–574. 2014. View Article : Google Scholar : PubMed/NCBI
8	Graf K and Schaefer-Graf UM: Is Smad3 the key to inflammation and fibrosis in hypertensive heart disease? Hypertension. 55:1088–1089. 2010. View Article : Google Scholar : PubMed/NCBI
9	Ferreira AS and Lopes AJ: Chinese medicine pattern differentiation and its implications for clinical practice. Chin J Integr Med. 17:818–823. 2011. View Article : Google Scholar : PubMed/NCBI
10	Xiang P, Deng HY, Li K, Huang GY, Chen Y, Tu L, Ng PC, Pong NH, Zhao H, Zhang L, et al: Dexrazoxane protects against doxorubicin-induced cardiomyopathy: Upregulation of Akt and Erk phosphorylation in a rat model. Cancer Chemother Pharmacol. 63:343–349. 2009. View Article : Google Scholar : PubMed/NCBI
11	Shen FF, Jiang TH, Jiang JQ, Lou Y and Hou XM: Traditional chinese medicine tongxinluo improves cardiac function of rats with dilated cardiomyopathy. Evid Based Complement Alternat Med. 2014:3238702014. View Article : Google Scholar : PubMed/NCBI
12	Qin YW, Ye P, He JQ, Sheng L, Wang LY and Du J: Simvastatin inhibited cardiac hypertrophy and fibrosis in apolipoprotein E-deficient mice fed a ‘Western-style diet’ by increasing PPAR α and γ expression and reducing TC, MMP-9, and Cat S levels. Acta Pharmacol Sin. 31:1350–1358. 2010. View Article : Google Scholar : PubMed/NCBI
13	Feng Y, Xu H and Chen K: Natural Polypill Xuezhikang: Its clinical benefit and potential multicomponent synergistic mechanisms of action in cardiovascular disease and other chronic conditions. J Altern Complement Med. 18:318–328. 2012. View Article : Google Scholar : PubMed/NCBI
14	Hayward R and Hydock DS: Doxorubicin cardiotoxicity in the rat: an in vivo characterization. J Am Assoc Lab Anim Sci. 46:20–32. 2007.PubMed/NCBI
15	Schwarz ER, Pollick C, Dow J, Patterson M, Birnbaum Y and Kloner RA: A small animal model of non-ischemic cardiomyopathy and its evaluation by transthoracic echocardiography. Cardiovasc Res. 39:216–223. 1998. View Article : Google Scholar : PubMed/NCBI
16	Barondes SH, Cooper DN, Gitt MA and Leffler H: Galectins. Structure and function of a large family of animal lectins. J Biol Chem. 269:20807–20810. 1994.PubMed/NCBI
17	Shah RV and Januzzi JL Jr: Soluble ST2 and galectin-3 in heart failure. Clin Lab Med. 34:87–97. 2014. View Article : Google Scholar : PubMed/NCBI
18	Wu AH, Wians F and Jaffe A: Biological variation of galectin-3 and soluble ST2 for chronic heart failure: Implication on interpretation of test results. Am Heart J. 165:995–999. 2013. View Article : Google Scholar : PubMed/NCBI
19	Yu L, Ruifrok WP, Meissner M, Bos EM, van Goor H, Sanjabi B, van der Harst P, Pitt B, Goldstein IJ, Koerts JA, et al: Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail. 6:107–117. 2013. View Article : Google Scholar : PubMed/NCBI
20	Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, André S, Crijns HJ, Gabius HJ, Maessen J, et al: Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 110:3121–3128. 2004. View Article : Google Scholar : PubMed/NCBI
21	Lax A, Sanchez-Mas J, Asensio-Lopez MC, Fernandez-Del Palacio MJ, Caballero L, Garrido IP, Pastor-Perez FJ, Januzzi JL and Pascual-Figal DA: Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction. JACC Heart Fail. 3:50–58. 2015. View Article : Google Scholar : PubMed/NCBI
22	Du J, Xie J, Zhang Z, Tsujikawa H, Fusco D, Silverman D, Liang B and Yue L: TRPM7-mediated Ca²⁺ signals confer fibrogenesis in human atrial fibrillation. Circ Res. 106:992–1003. 2010. View Article : Google Scholar : PubMed/NCBI
23	Dobaczewski M, Bujak M, Li N, Gonzalez-Quesada C, Mendoza LH, Wang XF and Frangogiannis NG: Smad3 signaling critically regulates fibroblast phenotype and function in healing myocardial infarction. Circ Res. 107:418–428. 2010. View Article : Google Scholar : PubMed/NCBI
24	Jia N, Dong P, Ye Y, Qian C and Dai Q: Allopurinol attenuates oxidative stress and cardiac fibrosis in angiotensin II-induced cardiac diastolic dysfunction. Cardiovasc Ther. 30:117–123. 2012. View Article : Google Scholar : PubMed/NCBI
25	Xiao H, Ma X, Feng W, Fu Y, Lu Z, Xu M, Shen Q, Zhu Y and Zhang Y: Metformin attenuates cardiac fibrosis by inhibiting the TGFβ1-Smad3 signalling pathway. Cardiovasc Res. 87:504–513. 2010. View Article : Google Scholar : PubMed/NCBI
26	Zhao M, Zheng S, Yang J, Wu Y, Ren Y, Kong X, Li W and Xuan J: Suppression of TGF-β1/Smad signaling pathway by sesamin contributes to the attenuation of myocardial fibrosis in spontaneously hypertensive rats. PLoS One. 10:e01213122015. View Article : Google Scholar : PubMed/NCBI
27	Ding YF, Peng YR, Li J, Shen H, Shen MQ and Fang TH: Gualou Xiebai Decoction prevents myocardial fibrosis by blocking TGF-β/Smad signalling. J Pharm Pharmacol. 65:1373–1381. 2013. View Article : Google Scholar : PubMed/NCBI
28	Shen N, Li X, Zhou T, Bilal MU, Du N, Hu Y, Qin W, Xie Y, Wang H, Wu J, et al: Shensong Yangxin Capsule prevents diabetic myocardial fibrosis by inhibiting TGF-β1/Smad signaling. J Ethnopharmacol. 157:161–170. 2014. View Article : Google Scholar : PubMed/NCBI